Financial Performance - The company's revenue for Q1 2024 was ¥78,457,398.26, representing a 0.48% increase compared to ¥78,085,173.39 in the same period last year[5] - The net loss attributable to shareholders was ¥2,537,276.14, a 4.97% increase from a loss of ¥2,417,228.83 in the previous year[5] - Net profit for Q1 2024 was a loss of CNY 3,574,947.54, compared to a loss of CNY 2,520,711.19 in Q1 2023, reflecting a deterioration in performance[19] - The total comprehensive income for Q1 2024 was a loss of CNY 3,574,947.54, compared to a gain of CNY 5,380,673.81 in Q1 2023[19] - Basic and diluted earnings per share remained at -0.03, unchanged from the previous year[19] Cash Flow - The net cash flow from operating activities was negative at ¥12,916,651.56, a significant decline of 173.09% compared to a positive cash flow of ¥17,673,168.97 in the same period last year[5] - The company reported a net cash outflow from operating activities of CNY 12,916,651.56, contrasting with a net inflow of CNY 17,673,168.97 in the previous year[20] - The net cash flow from investment activities was -222,803,655.48 CNY, compared to a positive cash flow of 9,231,859.19 CNY in the previous period[21] - The company reported a total cash outflow from investment activities of 514,784,910.91 CNY, significantly higher than 157,342,578.00 CNY in the previous period[21] - Total cash inflow from financing activities amounted to 95,800,480.00 CNY, an increase from 50,000,000.00 CNY in the prior period[21] - The net cash flow from financing activities was 74,334,232.97 CNY, compared to 49,538,750.00 CNY previously[21] - The ending balance of cash and cash equivalents was 167,616,498.27 CNY, down from 500,489,923.64 CNY at the beginning of the period[21] - Cash received from sales of goods and services was CNY 78,612,207.69, down from CNY 104,356,664.61 in the same period last year[20] - Cash received from investment activities was 291,981,255.43 CNY, compared to 166,574,437.19 CNY previously[21] - The cash outflow for debt repayment was 128,000.00 CNY, with dividend payments totaling 1,339,236.54 CNY[21] Assets and Liabilities - Total assets increased by 19.77% to ¥1,116,427,033.08 from ¥932,156,719.79 at the end of the previous year[5] - The total liabilities of the company reached CNY 317,245,144.19, compared to CNY 250,588,538.76 at the beginning of the period, reflecting an increase of approximately 26.5%[14] - The company's current assets totaled CNY 682,373,216.45, up from CNY 648,948,030.89 at the start of the quarter, reflecting a growth of approximately 5.5%[13] - The company's short-term borrowings increased to CNY 74,942,925.06 from CNY 50,129,622.69, marking a rise of approximately 49.6%[14] - Long-term borrowings rose significantly to CNY 188,216,919.88 from CNY 118,080,017.10, indicating an increase of about 59.4%[14] - The total assets of Tibet Duorui Pharmaceutical Co., Ltd. as of March 31, 2024, amounted to CNY 1,116,427,033.08, an increase from CNY 1,072,265,596.55 at the beginning of the period[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,628[10] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of the shares, amounting to 46,677,966 shares, with 12,050,000 shares pledged[10] - The total equity attributable to shareholders of the parent company decreased to CNY 749,545,110.89 from CNY 772,064,892.00 at the end of the previous period[18] Operating Costs and Expenses - The operating costs surged by 72.44% to ¥47,485,816.29, attributed to an increase in the sales proportion of low-margin products[8] - Total operating costs increased to CNY 84,406,149.31, up 2.66% from CNY 81,960,671.26 year-over-year[17] - Research and development expenses decreased by 55.87% to ¥3,017,966.19, indicating a slowdown in R&D investment compared to the previous year[8] - Research and development expenses decreased to CNY 3,017,966.19, down 55.9% from CNY 6,839,149.50 in the same quarter last year[17] - The company experienced a 111.40% increase in financial expenses, amounting to ¥150,342.17, due to a rise in average borrowings[8] Other Information - The company did not undergo an audit for the first quarter report[22] - The report indicates the implementation of new accounting standards starting in 2024[22] - The company received 900,000.00 CNY from investment contributions[21] - The company reported an increase in other non-current assets to CNY 16,176,562.00 from CNY 16,327,323.75, a slight decrease of about 0.9%[14] - Inventory levels slightly decreased to CNY 31,374,246.99 from CNY 33,128,080.17, a decline of about 5.3%[13] - The accounts receivable rose to CNY 82,849,569.79 from CNY 79,736,341.25, showing an increase of approximately 3.5%[13] - The company recorded investment income of CNY 2,467,690.07, significantly higher than CNY 852,902.18 in the previous year[17]
多瑞医药(301075) - 2024 Q1 - 季度财报